Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 3, 2006, Pages 387-396

  Dilger, K ^a   Alberer, M ^b   Busch, A ^c   Enninger, A ^d   Behrens, R ^e   Koletzko, S ^b   Stern, M ^c   Beckmann, C ^c   Gleiter, C H ^c  

^a Dr Falk Pharma GmbH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d OLGAHOSPITAL   (Germany)

^e Children's Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYPREDNISOLONE; 6BETA HYDROXYBUDESONIDE; AZATHIOPRINE; BUDESONIDE; CYTOCHROME P450 3A; DRUG METABOLITE; HYDROCORTISONE; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADRENAL SUPPRESSION; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HUMANS; HYDROCORTISONE; MALE;

EID: 33644921473     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02771.x     Document Type: Article

References (33)

1. Kearns GL Abdel-Rahman SM Alander SW Blowey DL Leeder JS Kauffman RE Developmental pharmacology - drug disposition, action, and therapy in infants and children N Engl J Med 2003 349 1157 67
2. Kim SC Ferry GD Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations Gastroenterology 2004 126 1550 60
3. Fedorak RN Bistritz L Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide Adv Drug Deliv Rev 2005 57 303 16
4. Bar-Meir S Chowers Y Lavy A et al. Budesonide versus prednisone in the treatment of active Crohn's disease Gastroenterology 1998 15 835 40
5. Papi C Luchetti R Gili L Montanti S Koch M Capurso L Budesonide in the treatment of Crohn's disease: a meta-analysis Aliment Pharmacol Ther 2000 14 1419 28
6. Levine A Weizman Z Broide E et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease J Pediatr Gastroenterol Nutr 2003 36 248 52
7. Escher JC the European Collaborative Research Group on Budesonide in Paediatric IBD Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial Eur J Gastroenterol Hepatol 2004 16 47 54
8. Dilger K Schwab M Fromm MF Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein Inflamm Bowel Dis 2004 10 578 83
9. Jonsson G Astrom A Andersson P Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver Drug Metab Dispos 1995 23 137 42
10. Guengerich FP Cytochrome P-450 3A4: regulation and role in drug metabolism Annu Rev Pharmacol Toxicol 1999 39 1 17
11. de Wildt SN Kearns GL Leeder JS van den Anker JN Cytochrome P450 3A. Ontogeny and drug disposition Clin Pharmacokinet 1999 37 485 505
12. Fakhoury M Litalien C Medard Y et al. Localization and mRNA expression of CYP3A and P-gp in human duodenum as a function of age Drug Metab Dispos 2005 33 1603 7
13. Greenberg GR Feagan BG Martin F et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group N Engl J Med 1994 331 836 41
14. Hyams JS Ferry GD Mandel FS et al. Development and validation of a pediatric Crohn's disease activity index J Pediatr Gastroenterol Nutr 1991 12 439 47
15. Flockhart DA Drug Interactions - Cytochrome P450 System Available at:. Last accessed 23 December 2004 q2
16. Schwab M Schaeffeler E Marx C et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis Gastroenterology 2003 124 26 33
17. Wang Y Tang Y Moellmann H Hochhaus G Simultaneous quantification of budesonide and its two metabolites, 6β-hydroxybudesonide and 16α-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry Biomed Chromatogr 2003 17 158 64
18. Rowland M Tozer T Clinical Pharmacokinetics. Concepts and Applications 3rd edn Baltimore, USA Williams & Wilkins 1995
19. CDER General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products Available at:. Last accessed 21 December 2005 q3
20. Dilger K Denk A Heeg MHJ Beuers U No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis Hepatology 2005 41 595 602
21. Hoffmeyer S Burk O von Richter O et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 2000 97 3473 8
22. Lundin PDP Edsbacker S Bergstrand M et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease Aliment Pharmacol Ther 2003 17 85 92
23. Shimada T Yamazaki H Mimura M Inui Y Guengerich FP Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 1994 270 414 23
24. Xie HG Wood AJJ Kim RB Stein CM Wilkinson GR Genetic variability in CYP3A5 and its possible consequences Pharmacogenomics 2004 5 243 72
25. Lacroix D Sonnier M Moncion A Cheron G Cresteil T Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth Eur J Biochem 1997 247 625 34
26. Oesterheld JR A review of developmental aspects of cytochrome P450 J Child Adolesc Psychopharmacol 1998 8 161 74
27. Johnson TN Tanner MS Taylor CJ Tucker GT Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of celiac disease and cystic fibrosis Br J Clin Pharmacol 2001 51 451 60
28. Stevens JC Hines RN Gu C et al. Developmental expression of the major human hepatic CYP3A enzymes J Pharmacol Exp Ther 2003 307 573 82
29. Edsbacker S Bengtsson B Larsson P et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules Aliment Pharmacol Ther 2003 17 525 36
30. Zhang Y Benet LZ The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein Clin Pharmacokinet 2001 40 159 68
31. Marzolini C Paus E Buclin T Kim RB Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 2004 75 13 33
32. Escher JC Taminiau JAJM Nieuwenhuis EES Büller HA Grand RJ Treatment of inflammatory bowel disease in childhood: best available evidence Inflamm Bowel Dis 2003 9 34 58
33. Jonetz-Mentzel L Wiedemann G Establishment of reference ranges for cortisol in neonates, infants, children and adolescents Eur J Clin Chem Clin Biochem 1993 31 525 9